← feed

Is NCT02055183 results overdue?

Yes — results are overdue. Primary completion was 2017-07; the FDAAA-801 reporting deadline (2018-07-31) passed 2882 days ago and no results are posted on ClinicalTrials.gov.

BT-010 Registry for the Evaluation of Safety and Clinical Outcomes in Patients Treated With Botulinum Antitoxin

NCT IDNCT02055183 ↗
SponsorEmergent BioSolutions (INDUSTRY)
Public issuerEmergent BioSolutions Inc. — EBS (CIK 0001367644) best-effort name match, 95% conf — verify on EDGAR ↗
Phase
StatusCOMPLETED
Primary completion2017-07 (ACTUAL)
Reporting deadline2018-07-31 (completion + 365d)
Days overdue2882
Results postedNo — check results tab ↗
FDA-regulateddrug: yes, device: no
ProvenanceFlagged overdue on 2026-06-21 · SHA-256 c69b9b00db98bf81… (hash-chained, tamper-evident)

Source of record: ClinicalTrials.gov NCT02055183. The reporting requirement is FDAAA 801 (Public Law 110-85 §801) and the Final Rule, 42 CFR Part 11.

⚠ Public-record facts from ClinicalTrials.gov — not a finding of violation, fraud, or non-compliance, and not legal or investment advice. Full disclaimer →